ASP Isotopes Inc. (ASPI)
NASDAQ: ASPI · IEX Real-Time Price · USD
3.070
-0.210 (-6.40%)
At close: Jul 2, 2024, 4:00 PM
3.100
+0.030 (0.98%)
After-hours: Jul 2, 2024, 7:27 PM EDT
Company Description
ASP Isotopes Inc., a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes.
It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28.
The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
ASP Isotopes Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Nov 10, 2022 |
| Industry | Chemicals |
| Sector | Materials |
| Employees | 76 |
| CEO | Paul Elliot Mann |
Contact Details
Address: 1101 Pennsylvania Avenue Nw, Suite 300 Washington, District of Columbia 20004 United States | |
| Phone | 202-756-2245 |
Stock Details
| Ticker Symbol | ASPI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001921865 |
| CUSIP Number | 00218A105 |
| ISIN Number | US00218A1051 |
| Employer ID | 87-2618235 |
| SIC Code | 2890 |
Key Executives
| Name | Position |
|---|---|
| Paul Elliot Mann | President, Chief Executive Officer and Executive Chairman |
| Robert Ainscow | Chief Financial Officer and Chief Operating Officer |
| Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D. | Chief Technology Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 10-K/A | [Amend] Annual report |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 12, 2024 | EFFECT | Notice of Effectiveness |
| Jun 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 12, 2024 | 424B5 | Filing |
| Jun 6, 2024 | 8-K | Current Report |
| May 31, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 22, 2024 | 424B3 | Prospectus |
| May 21, 2024 | EFFECT | Notice of Effectiveness |